Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $56.3 million.

  • Spero Therapeutics' Shares Outstanding (Weighted Average) rose 398.33% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 398.33%. This contributed to the annual value of $54.0 million for FY2024, which is 253.2% up from last year.
  • As of Q3 2025, Spero Therapeutics' Shares Outstanding (Weighted Average) stood at $56.3 million, which was up 398.33% from $56.0 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' Shares Outstanding (Weighted Average) peaked at $56.3 million during Q3 2025, and registered a low of $29.4 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $45.0 million, with a median of $52.6 million in 2023.
  • In the last 5 years, Spero Therapeutics' Shares Outstanding (Weighted Average) surged by 6109.26% in 2023 and then surged by 189.81% in 2024.
  • Spero Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $30.9 million in 2021, then increased by 21.65% to $37.6 million in 2022, then surged by 40.22% to $52.7 million in 2023, then rose by 2.53% to $54.0 million in 2024, then increased by 4.15% to $56.3 million in 2025.
  • Its last three reported values are $56.3 million in Q3 2025, $56.0 million for Q2 2025, and $55.4 million during Q1 2025.